Sugi Predict

Sugi Predict / Targets / BLK

BLK

Tyrosine-protein kinase Blk · P51451 · BLK on Sugi Atlas →

98,267 patent compounds predicted against BLK, 78,413 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Linifanib Linifanib (SCHEMBL93804) 1.00 6/20
SCHEMBL90887 SCHEMBL90887 0.49 6/20
SCHEMBL90935 SCHEMBL90935 0.49 6/20
SCHEMBL60289 SCHEMBL60289 0.48 5/20
SCHEMBL58735 SCHEMBL58735 0.47 5/20
SCHEMBL147422 SCHEMBL147422 0.66 4/20
SCHEMBL58313 SCHEMBL58313 0.59 4/20
SCHEMBL58543 SCHEMBL58543 0.57 4/20
SCHEMBL60464 SCHEMBL60464 0.57 4/20
SCHEMBL144979 SCHEMBL144979 0.56 4/20
SCHEMBL58550 SCHEMBL58550 0.55 4/20
SCHEMBL58416 SCHEMBL58416 0.50 4/20
SCHEMBL59547 SCHEMBL59547 0.49 4/20
SCHEMBL66159 SCHEMBL66159 0.49 4/20
SCHEMBL60366 SCHEMBL60366 0.45 4/20
SCHEMBL58496 SCHEMBL58496 0.44 4/20
SCHEMBL58420 SCHEMBL58420 0.43 4/20
SCHEMBL59205 SCHEMBL59205 0.42 4/20
SCHEMBL95142 SCHEMBL95142 1.00 3/20
SCHEMBL94964 SCHEMBL94964 0.79 3/20

Clinical trials — most relevant to BLK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers PHASE3UNKNOWN
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma PHASE3UNKNOWN
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP PHASE1/PHASE2COMPLETED
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation PHASE2COMPLETED
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus PHASE1/PHASE2RECRUITING
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL PHASE2RECRUITING
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia PHASE2ACTIVE_NOT_RECRUITING
CML Treated With Bosutinib After Relapse PHASE2COMPLETED
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia PHASE1/PHASE2WITHDRAWN
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase PHASE2COMPLETED
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL PHASE1/PHASE2UNKNOWN
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy PHASE1COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE1COMPLETED
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BLK binder may also engage these)

ProteinNameSimilarity
P00526 — 0.999 P00526 →
HCK Tyrosine-protein kinase HCK 0.999 landscape →
P31693 — 0.999 P31693 →
Q6P6U0 — 0.998 Q6P6U0 →
Q6EWH2 — 0.998 Q6EWH2 →
P00524 — 0.997 P00524 →
Q1JPZ3 — 0.996 Q1JPZ3 →
Q01621 — 0.995 Q01621 →
P16277 — 0.994 P16277 →
Q95KR7 — 0.994 Q95KR7 →
P00523 — 0.993 P00523 →
A1Y2K1 — 0.993 A1Y2K1 →
FRK Tyrosine-protein kinase FRK 0.993 landscape →
P00527 — 0.992 P00527 →
P27447 — 0.992 P27447 →
P50545 — 0.992 P50545 →
FGR Tyrosine-protein kinase Fgr 0.992 landscape →
P63185 — 0.992 P63185 →
A0JNB0 — 0.992 A0JNB0 →
P13116 — 0.991 P13116 →
Q5PXS1 — 0.991 Q5PXS1 →
Q922K9 — 0.991 Q922K9 →
P13406 — 0.990 P13406 →
Q95M30 — 0.990 Q95M30 →
P27446 — 0.990 P27446 →
Q9WUD9 — 0.990 Q9WUD9 →
P10447 — 0.990 P10447 →
P06240 — 0.990 P06240 →
Q62844 — 0.990 Q62844 →
P09324 — 0.989 P09324 →